Piramal Pharma Announces Q4 and Full-Year FY26 Results, Points to Growth Momentum in FY27

Piramal Pharma Announces Q4 and Full-Year FY26 Results, Points to Growth Momentum in FY27​

Piramal Pharma Limited, a global pharmaceutical and health and wellness company, announced its standalone and consolidated financial results for the Fourth Quarter (Q4) and Full-year ended March 31, 2026. The results highlight the performance of its key segments, including Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and Piramal Consumer Healthcare (PCH).

Consolidated Financial Highlights​

The company reported consolidated financial metrics for FY26, noting that full-year reported growth was impacted by inventory destocking, slower early-stage order inflows in H1FY26, and softer ex-US inhalation anesthesia traction.

The financial data for the quarter and full year are summarized below (in ₹ Crores):


On the balance sheet, the company reported Total Equity of 8,162 (₹ Cr.) as of March 31, 2026, compared to 8,125 (₹ Cr.) on the previous year. Net Debt stood at 4,140 (₹ Cr.) in FY26, showing no increase over FY25.

Key Business Segment Updates​

Contract Development and Manufacturing Organization (CDMO)
The CDMO business is benefiting from strong customer interest and visible momentum. Key achievements include:

• Growth Drivers: Healthy traction in RFPs and order inflows in H2FY26, driven by stronger US biopharma funding (up YoY 75% in H2FY26, 30% in FY26) and M&A activity.
• Capacity Expansion: US$90Mn Capex is on track to scale sterile injectable and payload-linker capacities at Lexington and Riverview sites.
• Operational Metrics: The company achieved a Net Promoter Score of 60, surpassing the industry average, and conducted 209 customer site audits in FY26, up from 165 in FY25.

Complex Hospital Generics (CHG)
The CHG segment expanded its portfolio through the completion of the Kenalog® acquisition.

• Acquisition Details: The transaction involved an upfront consideration of US$35Mn and contingent consideration of up to US$65Mn.
• Market Leadership: The CHG business maintains a leading position in the US market for Inhalation Anesthesia (IA), retaining a 47% market share (up from 45% in March 2024). It also maintains the #1 Rank in the US Intrathecal Baclofen segment.

Piramal Consumer Healthcare (PCH)
The PCH business demonstrated strong growth in FY26.

• Power Brands: Power Brands contributed 52% to total PCH sales and achieved 24% YoY growth in FY26, led by Little's, Lacto Calamine, CIR, and i-range.
• E-commerce: E-commerce sales grew at 48% rate YoY in FY26, contributing approximately 27% to PCH sales.

Management Outlook​

Nandini Piramal, Chairperson, Piramal Pharma Limited, stated that FY26 was a transitional year influenced by external disruptions and business-specific factors. Despite this, she noted the company exited the year with clear momentum across all businesses.

Management highlighted that the meaningful recovery in biopharma funding, observed since September 2025, is translating into good RFP momentum and increased order inflows in the CDMO business.

Looking ahead, the company anticipates delivering growth in FY27 across all three businesses, alongside accelerated growth in EBITDA and PAT. The strategy for the coming year involves continued investment in high-potential areas, including:

• Scaling sterile injectable and payload-linker capacities at Lexington and Riverview sites with US$90Mn investment.
• Further expanding the distribution network by focusing on Tier 3/4 towns and increasing presence in Modern Trade.
• Focusing on building a differentiated and specialty product pipeline, especially within the CDMO segment.

PPLPHARMA Stock Price Movement​

On Tuesday, Piramal Pharma Limited shares slipped by 2.33% to close at ₹164.47. The equity settled on significant volume, processing over 6.02 million shares throughout the trading day.